You are here: Industry Insights > Skyrizi

News List

FDA expands approval for AbbVie’s Skyrizi for active psoriatic arthritis Pharmaceutical-Technology
January 26, 2022
The FDA approval is based on data from two Skyrizi Phase III trials, KEEPsAKE-1 and KEEPsAKE-2.
US FDA approves second indication for Skyrizi to treat adults with active psoriatic arthritis ExpressPharma
January 24, 2022
AbbVie recently announced that the US Food and Drug Administration (FDA) has approved Skyrizi (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA)...
AbbVie's 2Q Revenue up 34% contractpharma
August 02, 2021
New immunology assets Skyrizi and Rinvoq contribute more than $1 billion of combined sales in the quarter.
Abbvie's 1Q Reveneus up 51% contractpharma
May 06, 2021
Aesthetics portfolio drives growth in the quarter with Botox Cosmetic sales up 45%.
AbbVie presents applications to FDA and EMA for approval of SKYRIZI in psoriatic arthritis pharmaceutical-business-review
April 09, 2021
AbbVie has submitted applications seeking approval for SKYRIZI (risankizumab-rzaa, 150 mg) and SKYRIZI (risankizumab, 150 mg) to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), respectively, for the treatment of ...
Skyrizi bags positive psoriatic arthritis results pharmatimes
January 08, 2021
AbbVie and Boehringer Ingelheim’s Skyrizi (risankizumab) has scored positive top-line results from two phase III studies in adults with active psoriatic arthritis.
AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib fiercepharma
July 29, 2019
AbbVie is in the early stages of its Humira biosimilar slide after European copycats rolled out last fall. But thankfully for the drugmaker, it has a psoriasis launch handily besting expectations.
AbbVie pads Humira follow-up Skyrizi's blockbuster potential with positive 2-year data fiercepharma
June 12, 2019
AbbVie already has high hopes for newly approved immunology drug Skyrizi as its old megablockbuster Humira starts to fall.
AbbVie expands immunology portfolio in the U.S. with FDA approval of SKYRIZI™ biospectrumasia
April 28, 2019
AbbVie recently received approval of SKYRIZI from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis
AbbVie, Boehringer Ingelheim's IL-23 inhibitor Skyrizi gains US approval for plaque psoriasis firstwordpharma
April 25, 2019
AbbVie announced that the FDA approved Skyrizi (risankizumab-rzaa) for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Previous page 1 2 Next page